Publications
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial +12012 | First Faculty of Medicine
- Treatment of multiple myeloma with lenalidomide in 20122012 | First Faculty of Medicine
- Lenalidomide in the first and additional lines of therapy for multiple myeloma2012 | First Faculty of Medicine
- Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report2012 | First Faculty of Medicine
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study2011 | First Faculty of Medicine
- An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation2011 | First Faculty of Medicine
- Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial2010 | First Faculty of Medicine
- Autologous stem cell transplantation for AL amyloidosis –single-center results of a strict risk-adapted approach.2010 | First Faculty of Medicine
Loading network view...